It aids in determining a patient's response to therapy and guides further treatment decisions. MRD testing uses highly sensitive techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to detect presence of one cancer cell amongst 100,000 normal cells. This helps increase the chances of long-term remission and improves outcomes for cancers like acute lymphoblastic leukemia, multiple myeloma, and mantle cell lymphoma. Growing awareness about benefits of MRD monitoring and increasing prevalence of cancers globally are fueling adoption of MRD testing solutions.

The global minimal residual disease testing market is estimated to be valued at US$ 4.97 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the minimal residual disease testing market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.

The rising incidence of hematological cancers and initiatives to enhance treatment outcomes are fueling demand for MRD testing. According to Globocan 2020, around 10.4 million new cancer cases and 6.2 million cancer deaths were reported worldwide in 2020. Availability of sensitive and accurate MRD testing aids in monitoring disease progression and guides targeted therapy administration.

Technological advancements are expanding applications of MRD testing. Real-time quantitative PCR and next-generation sequencing allow detection of MRD even at very low levels of 0.001%. Development of personalized MRD testing using panels tailored for individual cancer types further enhances accuracy and sensitivity. Combining MRD testing with artificial intelligence can help predict patient outcomes more precisely.

Market Trends

Growing adoption of personalized medicine: Personalized MRD testing tailored for specific cancer types and patient profiles helps guide more effective treatment decisions. Combining genomic profiling with MRD monitoring also aids in personalized therapy selection.

Integration with liquid biopsy: Integration of Minimal Residual Disease Testing Market Size with liquid biopsy allows non-invasive monitoring of disease burden using blood samples. This overcomes limitations of traditional invasive tissue biopsies and improves patient outcomes and experience.

Get more insights on This Topic- Minimal Residual Disease Testing Market